Patient preference trial comparing capecitabine and S-1 in metastatic breast cancer patients.

Patient preference trial comparing capecitabine and S-1 in metastatic breast cancer patients. - Patient preference trial comparing capecitabine and S-1 in metastatic breast cancer patients.

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000013045

Enrollment

Registered

2014-02-03

Start date

2014-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

metastatic breast carcinoma

Interventions

capecitabine S-1

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: metastatic breast cancer patient

Exclusion criteria

Exclusion criteria: ECOG performance status is more than 3

Design outcomes

Primary

Measure	Time frame
patient preference	—

Secondary

Measure	Time frame
PFS, OS, address quality of life (EORTC-30), and anxiety and depression (HADS)	—

Countries

Japan

Contacts

Public ContactDaigo Yamamoto

JBCRN breast unit

yamamotd@takii.kmu.ac.jp0669921001

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026